Use of transfected or transduced mammalian cells for treating bone pathologies
CA 2308511 C · Owner: Robbins, Paul D. · Inventors: Whalen, Janey D.; Robbins, Paul D.; Lattermann, Christian
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of a vector selected from the group consisting of , adenoviruses, adeno-associated viruses retroviruses and plasmids as agents , for ex vivo transfection or transduction of mammalian osteoblasts to produce therapeutic proteins acting as , medicaments for the treatment of a bone pathology selected from the group consisting of local , or systemic bone mass loss bone substance loss or bone structure disorders bone fractures , with bone substance loss defect fractures, pseudoarthrosis, Sudek's disease bone defect , conditions after operations bone substance loss in endoprothesis loosening periarticular , osteolysis, rheumatic diseases and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 29, 1998 and granted January 19, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 29, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 29, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.